Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. - Yi, Zongbi; Ma, Fei; Liu, Binliang; Guan, Xiuwen; Li, Lixi; Li, Chunxiao; Qian, Haili; Xu, Binghe (BMC Cancer, 2019)